These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 1571708)
1. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow. Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708 [TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells. Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323 [TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors. Lemoli RM; Gulati SC Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748 [TBL] [Abstract][Full Text] [Related]
4. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells. Gidáli J; Fehér I Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197 [TBL] [Abstract][Full Text] [Related]
5. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213). Deconinck E; Tamayo E; Hervé P Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow. De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785 [TBL] [Abstract][Full Text] [Related]
7. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495 [TBL] [Abstract][Full Text] [Related]
8. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001 [TBL] [Abstract][Full Text] [Related]
10. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404 [TBL] [Abstract][Full Text] [Related]
11. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation. Makrynikola V; Kabral A; Bradstock KF Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969 [TBL] [Abstract][Full Text] [Related]
12. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study. Miller G; Brashear T; Stone M; Fay J Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738 [TBL] [Abstract][Full Text] [Related]
13. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells. Gidáli J; Fehér I; Kovács P Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126 [TBL] [Abstract][Full Text] [Related]
14. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. Grant S; Bhalla K; Arlin Z; Howe CW Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268 [TBL] [Abstract][Full Text] [Related]
15. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells. Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386 [TBL] [Abstract][Full Text] [Related]
16. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation. Lopez M; Mary JY; Sainteny F Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567 [TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of combination drug purging for autologous bone marrow transplantation. Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626 [TBL] [Abstract][Full Text] [Related]
18. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow. Mumcuoglu M; Naparstek E; Slavin S Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907 [TBL] [Abstract][Full Text] [Related]
19. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. Yamazaki T; Sato Y; Sieber F Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739 [TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow. Tamayo E; Hervé P Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]